175 related articles for article (PubMed ID: 8855853)
1. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.
Jick H; Derby LE; Myers MW; Vasilakis C; Newton KM
Lancet; 1996 Oct; 348(9033):981-3. PubMed ID: 8855853
[TBL] [Abstract][Full Text] [Related]
2. Risk of venous thromboembolism in users of hormone replacement therapy.
Daly E; Vessey MP; Hawkins MM; Carson JL; Gough P; Marsh S
Lancet; 1996 Oct; 348(9033):977-80. PubMed ID: 8855852
[TBL] [Abstract][Full Text] [Related]
3. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.
Scarabin PY; Oger E; Plu-Bureau G;
Lancet; 2003 Aug; 362(9382):428-32. PubMed ID: 12927428
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of exogenous hormones and risk of pulmonary embolism in women.
Grodstein F; Stampfer MJ; Goldhaber SZ; Manson JE; Colditz GA; Speizer FE; Willett WC; Hennekens CH
Lancet; 1996 Oct; 348(9033):983-7. PubMed ID: 8855854
[TBL] [Abstract][Full Text] [Related]
5. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
Canonico M; Oger E; Plu-Bureau G; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
Circulation; 2007 Feb; 115(7):840-5. PubMed ID: 17309934
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD.
Ishiguro C; Wang X; Li L; Jick S
Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1168-75. PubMed ID: 25195779
[TBL] [Abstract][Full Text] [Related]
7. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.
Bergendal A; Kieler H; Sundström A; Hirschberg AL; Kocoska-Maras L
Menopause; 2016 Jun; 23(6):593-9. PubMed ID: 27023862
[TBL] [Abstract][Full Text] [Related]
8. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
Beral V; Bull D; Reeves G;
Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
[TBL] [Abstract][Full Text] [Related]
9. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study.
Canonico M; Oger E; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
J Thromb Haemost; 2006 Jun; 4(6):1259-65. PubMed ID: 16706969
[TBL] [Abstract][Full Text] [Related]
10. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.
Canonico M; Bouaziz E; Carcaillon L; Verstuyft C; Guiochon-Mantel A; Becquemont L; Scarabin PY;
J Clin Endocrinol Metab; 2008 Aug; 93(8):3082-7. PubMed ID: 18628519
[TBL] [Abstract][Full Text] [Related]
11. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women.
Olié V; Plu-Bureau G; Conard J; Horellou MH; Canonico M; Scarabin PY
Menopause; 2011 May; 18(5):488-93. PubMed ID: 21178641
[TBL] [Abstract][Full Text] [Related]
12. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study.
Le Gal G; Kovacs MJ; Carrier M; Do K; Kahn SR; Wells PS; Anderson DA; Chagnon I; Solymoss S; Crowther M; Righini M; Lacut K; White RH; Vickars L; Rodger M
Thromb Haemost; 2010 Sep; 104(3):498-503. PubMed ID: 20539910
[TBL] [Abstract][Full Text] [Related]
13. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.
Renoux C; Dell'aniello S; Garbe E; Suissa S
BMJ; 2010 Jun; 340():c2519. PubMed ID: 20525678
[TBL] [Abstract][Full Text] [Related]
14. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.
Beresford SA; Weiss NS; Voigt LF; McKnight B
Lancet; 1997 Feb; 349(9050):458-61. PubMed ID: 9040575
[TBL] [Abstract][Full Text] [Related]
15. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
Straczek C; Oger E; Yon de Jonage-Canonico MB; Plu-Bureau G; Conard J; Meyer G; Alhenc-Gelas M; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
Circulation; 2005 Nov; 112(22):3495-500. PubMed ID: 16301339
[TBL] [Abstract][Full Text] [Related]
16. HRT and the risk of deep vein thrombosis.
Barlow DH
Int J Gynaecol Obstet; 1997 Oct; 59 Suppl 1():S29-33. PubMed ID: 9386213
[TBL] [Abstract][Full Text] [Related]
17. Hormone therapy and venous thromboembolism among postmenopausal women.
Scarabin PY
Front Horm Res; 2014; 43():21-32. PubMed ID: 24943295
[TBL] [Abstract][Full Text] [Related]
18. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
19. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
20. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.
Bouligand J; Cabaret O; Canonico M; Verstuyft C; Dubert L; Becquemont L; Guiochon-Mantel A; Scarabin PY;
Clin Pharmacol Ther; 2011 Jan; 89(1):60-4. PubMed ID: 21107315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
